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Summary
Objective: To evaluate the beneﬁt of shortwave diathermy (SWD) supplemented to an exercise program for knee osteoarthritis (OA) in peri-/
post-menopausal women.
Methods: A double-blind randomized placebo-controlled equivalence trial was conducted in a university hospital. Participants including 113
women aged 50e85 years with primary knee OA were instructed to do regular quadriceps exercise, and randomized to control (n¼ 60)
and treatment (n¼ 53) groups receiving sham SWD and therapeutic SWD, respectively. The treatment being evaluated was continuous
SWD, 20 min/session, 3 sessions/week for 3 weeks. The outcomes including Thai Western Ontario and McMaster Universities OA (WOMAC)
index, 100-m walking speed, stair ascent-and-descent time, global assessment, patient’s satisfaction, and adverse events were assessed at
baseline and end of treatment.
Results: At the end of treatment, both groups had trivial but statistical improvement in all outcomes. Intention-to-treat analysis showed no
statistically signiﬁcant difference between the two groups in all outcomes. Per protocol analysis demonstrated the equivalence in Thai
WOMAC total score, as the 95% conﬁdence interval of difference (0.62, 0.92) was within conﬁdence limits of 1 cm.
Conclusion: The addition of SWD to an exercise program for knee OA in peri-/post-menopausal women is not superior to the exercise program
alone.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common degenerative joint
disorder, resulting in signiﬁcant morbidity and health care
expense1. It affects more than 60% of Western adults
over the age of 65 years2. It causes pain and dysfunction
in 20% of elderly persons3. The knee is the most commonly
affected joint found in one third of the population between
the ages of 63 and 94 years4. The community prevalence
of knee OA in Thailand is 34.5e45.6%5.
There are many treatment modalities for knee OA but
a curative method has not yet been discovered. Goals of
treatment as stated in various current recommendations,
including guidelines by the American College of Rheumatol-
ogy6 and European League Against Rheumatism (EULAR)7
focus on the relief of symptoms and the maintenance or the
improvement in functional status. Regarding the symptom-
atic relief, shortwave diathermy (SWD) is often prescribed
and is claimed to be effective. SWD is a form of electro-
magnetic therapy which produces an oscillating electromag-
netic ﬁeld, which causes movement of ions, distortion of1This trial is registered at www.ClinicalTrials.gov, trial number
NCT 00199914.
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823molecules, and creation of eddy currents, and as a result
heat is produced in deep tissue8. Its claimed mechanism
of action includes inducing an anti-inﬂammatory response9,
reducing joint stiffness10, stimulating connective tissue
repair11, and reducing muscle spasm and pain. However,
the efﬁcacy of SWD on knee OA is still inconclusive. Out-
comes of clinical trials vary from positive12e16 to null17e22
effects. The difference in such outcomes is largely due to
methodological deﬁciencies. Therefore, a double-blind ran-
domized, placebo-controlled trial with adequate power is
necessary to evaluate the effectiveness of SWD for the
treatment of knee OA. In the present study we evaluate
the beneﬁt of SWD supplemented to an exercise program
on the reduction of pain and the increment of function in
peri-/post-menopausal women with knee OA.Methods
A randomized and double-blind placebo-controlled equivalence trial was
carried out in the out-patient clinic, Department of Rehabilitation Medicine,
Faculty of Medicine, Siriraj Hospital, Mahidol University from January to
June 2004. The study was conducted in accordance with the ethical princi-
ples stated in the most recent version of the Declaration of Helsinki. The
study protocol was approved by the Ethic Committee of the Faculty of
Medicine, Siriraj Hospital.
The eligible patients were peri-/post-menopausal women aged 50e85
years. All patients had primary knee OA based on the diagnostic criteria of
the American College of Rheumatology23,24 and without the following condi-
tions: inability to walk, severe joint instability, history of previous SWD treat-
ment, intra-articular injection within 3 months, metallic implant around knee
joint, suspicious of malignancy around knee joint, signiﬁcant cardiovascular
disease, and inability to understand how to score the symptoms.
Treatment group
(n = 53)
Intention to treat analysis 
(n = 53) 
Per protocol analysis 
(n = 50, exclude dropouts) 
Dropouts (n = 3) 
- moved out (n = 1) 
- poor compliance (n = 1)
- knee operation (n = 1)
Dropouts (n = 6) 
- moved out (n = 3) 
- poor compliance (n = 3)
Control group
(n = 60)
Intention to treat analysis 
(n = 60) 
Per protocol analysis 
(n = 54, exclude dropouts) 
Randomized 
Enrollment
(N = 113)
Allocation
Follow-up
Analysis
Fig. 1. Flow of study participants: treatment¼SWDþ quadriceps exercise, control¼ sham SWDþ quadriceps exercise.
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to either a control or treatment group using a random number table. Each
treatment code was concealed in an opaque envelope, which was serially
opened by an independent physical therapist who performed the SWD
treatment accordingly. Only this physical therapist knew which treatment
was being provided to the patient. The physician who assessed the treat-
ment outcomes and the patient were unaware for the patient’s group of
treatment.
The patient lied on a treatment bed which had an opaque screen
between the bed and a SWD machine. The screen was used to blind the
patient from any procedure being performed on the SWD machine by the
physical therapist. The treatment group received continuous SWD using
an ULTRAMED (Bosch) model 11s601 serial number 3660340 with
a 10-cm diameter condenser plate operating at a frequency of 27.12 MHz,
an input of 300 W, and a mean output of 3.2 W. In each treatment session,Table I
Baseline characteristics of the ITT population (N¼ 113)
Characteristics Control
(n¼ 60)
Treatment
(n¼ 53)
Age (years) 62.48 8.47 63.32 7.61
Body mass
index (kg/m2)
26.17 4.15 25.64 4.03
Duration of
symptoms (years)
2.78 2.23 5.47 3.60
WOMAC total score 3.88 1.54 3.73 1.47
Pain subscale 3.73 1.71 3.87 1.72
Stiffness subscale 4.19 2.22 3.78 1.98
Function subscale 3.66 1.41 3.57 1.45
100-m walking
speed (m/min)
64.71 11.02 62.82 12.24
Stair ascent-and-
descent time (s)
25.45 8.93 28.81 14.92
Education 12 years 37 (61.67%) 33 (62.26%)
Active lifestyle 50 (83.33%) 46 (86.79%)
Bilateral affected site 26 (43.33%) 31 (58.49%)
Gait-aid use 4 (6.67%) 5 (9.43%)
Knee-support use 18 (30.00%) 21 (39.62%)
Data are meanSD or n (%).the condenser plate was wrapped around the affected knee(s) and the
power was on for 20 min. A course of treatment included nine SWD ses-
sions, which were completed in three consecutive weeks. The control group
received a sham SWD treatment, which had exactly the same treatment
procedure as the treatment group, except that the power switch was off.
At the end of the study period, each patient was asked to guess the treat-
ment group that she was in. This question was to assess the adequacy of
our blinding technique.
All patients were instructed to perform regular quadriceps exercise and
practice joint protection behavior. One cycle of quadriceps exercise com-
prised two steps: (1) isometric contraction held in full extension of knee for
5 s, and (2) isotonic resistive contraction held in mid ﬂexion of knee for
5 s. The patients were instructed to record exercise diaries which would be
used to assess the exercise compliance. The exercise compliance was cat-
egorized into three groups as follows: (1) good, exercise 50 repetitions/day
and 5 days/week; (2) fair, exercise 50 repetitions/day and <5 days/week,
or <50 repetitions/day and 5 days/week; and (3) poor, exercise <50 repe-
titions/day and <5 days/week.
The patients were allowed to take acetaminophen or a non-steroidal anti-
inﬂammatory drug (NSAID: Diclofenac sodium 25 mg) for pain relief as
needed. The medications were provided at each visit and the leftover pills
were returned for drug accountability at the subsequent visit. The patients
who took any analgesic medications during the 3-week treatment period
were classiﬁed as analgesic users. Concomitant medications, exercise fre-
quency, and potential adverse events were recorded.
The treatment would be terminated if: (1) the patient reported pain deteri-
oration, (2) the patients or doctor decided to stop, or (3) there were serious
complications such as severe joint effusion or acute joint inﬂammation. After
the end of the 3-week treatment period, the patients were advised to con-
tinue the quadriceps exercise.OUTCOME MEASURESThe baseline characteristics being collected included age, body mass in-
dex, duration of symptoms, education levels, lifestyle, number of affected
sites, and the use of gait-aid and knee-support.
The primary outcome was evaluated using a modiﬁed Thai version of
the Western Ontario and McMaster Universities OA (WOMAC) index.
The WOMAC index is a three dimensional, disease-speciﬁc, self-adminis-
tered health status instrument. The original version has 24 items in three
dimensions (ﬁve pain, two stiffness, and 17 function) valid for evaluating
symptoms and functions of the patients with hip or knee OA25; whereas
the modiﬁed Thai version has 22 items in three dimensions (ﬁve pain,
two stiffness, and 15 function) valid only for knee OA26. The response is
on 10-cm horizontal visual analog scales (VAS) with two descriptors, i.e.,
‘‘no symptom’’ or ‘‘no problem’’ at the left end, and ‘‘intolerable pain’’ or
Table II
Outcomes of treatment at the end of week 3 in per protocol population (N¼ 104)
Outcomes Control (n¼ 54) Treatment (n¼ 50) Mean difference
[95% CI]* or RR
(95% CI)
Py
Changes from baseline (delta)
Total WOMAC score 1.09 [1.55, 0.63] 1.04 [1.45, 0.62] 0.15 [0.62, 0.92]
Pain subscale 1.37 [1.88, 0.85] 1.30 [1.77, 0.83] 0.26 [0.59, 1.12]
Stiffness subscale 1.14 [1.81, 0.47] 1.04 [1.61, 0.47] 0.06 [1.16, 1.04]
Function subscale 0.68 [1.06, 0.29] 0.81 [1.19, 0.42] 0.11 [0.57, 0.80]
Walking speed (m/min) 0.97 [1.43, 3.36] 4.37 [2.51, 6.22] 2.35 [1.49, 6.18]
Stair ascent-and-descent time (s) 2.54 [4.27, 0.80] 4.45 [6.52, 2.38] 0.05 [3.26, 3.17]
Global assessment (score 1e6) 0.142
Improved (4e6) 26 (48.15%) 31 (62.00%)
Indifferent (2e3) 26 (48.15%) 15 (30.00%)
Deteriorated (1) 2 (3.70%) 4 (8.00%)
Satisfaction index (score 1e5) 0.208
Satisﬁed (4e5) 47 (87.00%) 45 (90.00%)
Indifferent (2e3) 7 (13.00%) 3 (6.00%)
Unsatisﬁed (1) 0 (0.00%) 2 (4.00%)
Analgesic usersz 32 (53.3%) 44 (83.0%) 1.80 (1.30, 2.47) 0.001
Exercise compliance (good) 31 (57.40%) 11 (22.00%) 0.50 (0.35, 0.72) 0.000
Data are mean [95% CI] or RR (95% CI) or n (%).
*Adjusted for duration of symptoms, analgesic use, and exercise compliance.
yUnpaired t test for continuous data or Chi-square test for categorical data.
zPatients who took any analgesic medications during the 3-week treatment period.
825Osteoarthritis and Cartilage Vol. 16, No. 7‘‘unable to do’’ at the right end. The score of each item therefore ranges
from 0 to 10. The higher score means the worse symptoms or functions.
The score of each dimension is the average of scores from all items in
the same dimension. The total WOMAC score is the average of scores
from all dimensions.
The secondary outcomes were as follows: (1) walking speed (the speed
of walking a 100-m distance, m/min); (2) stair ascent-and-descent time
(time to ascend and descend 12 steps of 18-cm step, s); (3) global
assessment (6-point Likert scales) categorized into deteriorated (score 1),
indifferent (score 2e3), and improved (score 4e6); and (4) patient’s
satisfaction index to the treatment (5-point Likert scales) categorized into
unsatisﬁed (score 1), indifferent (score 2e3), and satisﬁed (score 4e5).
The latter two outcomes were self-administered, except for the illiterate
or poor eyesight patient whose outcomes were assessed by an interviewer
who was a well-trained research assistant unaware of the patient’s treat-
ment group.
The outcomes were assessed at baseline (week 0), immediately after the
last SWD session (week 3), and at 3-week follow-up (week 6), except for the
global assessment and the satisfaction index that were assessed only at
week 3.SAMPLE SIZEThe sample size was calculated using a formula to detect the difference of
two independent means. When alpha¼ 0.05, power¼ 80%, minimal clini-
cally important improvement (MCII) of VAS knee OA¼ 1 cm27 and standard
deviation (SD) of difference deriving from our pilot study¼ 1.5, the sample
size was calculated at 36 per group to test the superiority of the additional
SWD over exercise alone. The sample size was also calculated to test the
equivalence since it was possible that the additional SWD might not be
beneﬁcial. When the power¼ 90% and other conditions were the same as
the above, the sample size was 48 per group. With 10% compensation,
the sample size of at least 53 per group would have adequate power to
detect both the superiority and the equivalence.STATISTICAL ANALYSISThe data were analyzed using SPSS for Windows, version 11.0.1. Data
were presented as mean SD, n (%), or line graph with error bar (SD). Com-
parative analysis was focused at the end of treatment (week 3). Within group
change from baseline value of a continuous variable was presented in mean
change (delta) and 95% conﬁdence interval (CI), and tested using a paired t
test; whereas between groups difference in the delta was tested using an
unpaired t test. The between group equivalence of the variable was demon-
strated using an adjusted mean difference of delta and 95% CI; the value ofwhich was adjusted for confounding factors using multiple linear regression.
The between groups comparison in global improvement and satisfaction
index were presented using relative risk (RR) and 95% CI, and tested using
Chi-square or Fisher’s exact test. Statistical analyses to test the superiority
were based on the intention-to-treat (ITT) population, and those chosen to
demonstrate the equivalence were based on the per protocol population.
The ‘‘worst-case-scenario’’ was applied to the dropouts in the ITT analyses.
All tests were two-sided, and had a signiﬁcant level at a P-value< 0.05. The
equivalence of the primary outcome (Thai WOMAC index) was considered
when the two-sided 95% CI for the between group difference in the Thai
WOMAC total score was within conﬁdence limits of 1 cm.
Results
Figure 1 shows ﬂow of the study participants. From Jan-
uary to June 2004, 113 eligible patients were randomized
into control group (sham SWD, n¼ 60) and treatment group
(SWD, n¼ 53). There were nine dropouts, six cases in the
control group (three moving out and three poor compliance)
and three cases in the treatment group (one moving out,
one knee operation, and one poor compliance). Character-
istics of all dropouts were similar to those of the completed
cases and their data were included in the ITT population.
Table I shows baseline and demographic data of the ITT
population. Data of the control and the treatment groups
were comparable except that the control group had a shorter
duration of symptoms (meanSD of control vs treatment,
2.55 1.85 vs 5.68 3.59 years).
Since the ITT analysis with the worst-case-scenario re-
vealed no statistical difference between the two groups
(data not shown); the per protocol analysis was performed
to demonstrate the equivalence. Table II, Figs. 2 and 3
show outcomes of the per protocol population. The within
group comparison demonstrated a statistically signiﬁcant
change from baseline in all continuous outcome variables
of both groups.
The between group comparison of the change from base-
line (delta) at week 3 was adjusted for confounding factors,
which were independent variables that were not compara-
ble between the two groups. Multiple linear regression
b Pain subscale
0 wk 3 wk 6 wk
5
4
3
2
1
c Stiffness subscale
0 wk 3 wk 6 wk
5
4
3
2
1
d Function subscale
0 wk 3 wk 6 wk
5
4
3
2
1
0 wk 3 wk 6 wk
Treatment
Control
a Total score
5
4
3
2
1
Treatment
Control
Treatment
Control
Treatment
Control
Fig. 2. Outcomes in the per protocol population: (a) WOMAC total score, (b) WOMAC pain subscale, (c) WOMAC stiffness subscale,
(d) WOMAC function subscale; WOMAC, modiﬁed Thai version; week 0e3¼ treatment period (quadriceps exerciseþSWD in the treatment
group or sham SWD in the control group), week 3e6¼ follow-up period (quadriceps exercise alone in both groups).
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(0¼ control and 1¼ treated), duration of symptoms
(0¼5 years and 1¼<5 years), exercise compliance
(0¼ poor and 1¼ good), and analgesic use (0¼ no and
1¼ yes). The adjusted mean difference of the deltas [95%
CI] of the Thai WOMAC total score (0.13 [0.68, 0.95]
cm) was within the equivalence limits of 1 cm. The
adjusted mean differences of deltas [95% CI] of other out-
comes including pain (0.26 [0.59, 1.12] cm), stiffness
(0.06 [1.16, 1.04] cm), function (0.11 [0.57, 0.80]
cm), walking speed (2.35 [1.49, 6.18] m/min), and stair
ascent-and-descent time (0.05 [3.26, 3.17] s) were not
statistically signiﬁcant. There were no differences in the
satisfaction index and global assessment scores between
the two groups.
Table III shows the adverse events of SWD and exercise.
The incidence of SWD side effects was similar in both40
30
20
10
b
Stair ascent-and-
descent time (s)
0 wk 3 wk 6 wk
80
70
60
50
a
Walking speed
(m/min)
0 wk 3 wk 6 wk
Treatment
Control
Treatment
Control
Fig. 3. Outcomes in the per protocol population: (a) walking speed,
(b) stair ascent-and-descent time; week 0e3¼ treatment period
(quadriceps exercise þSWD in the treatment group or sham
SWD in the control group), week 3e6¼ follow-up period (quadri-
ceps exercise alone in both groups).control and treatment groups (7.4% and 8.0%, respec-
tively). The events included mild pain, mild swelling and
feeling of vasodilatation. One patient in the treatment group
had deteriorating pain necessitating a knee operation. The
incidence of exercise side effects was also similar between
the two groups (33.9% and 37.0%, respectively). The
events included increasing crepitus sound, mild tightness
of muscle, fatigue, and mild pain.Discussion
The present double-blind, randomized, placebo-controlled
equivalence trial demonstrated that the use of SWD for the
symptomatic treatment of knee OA provided no additional
beneﬁt over the baseline treatment using quadriceps exer-
cise alone. SWD has been prescribed for various medical
conditions since the early twentieth century28 without deﬁnite
proof of its effect. Previous clinical studies of SWD effect on
OA showed either positive or null effect. The differences in
the outcomes are largely due to the difference in materials
and methods of the studies. The studies that demonstrated
positive effect have some methodological deﬁciency, e.g.,
lacking or using inappropriate control groups12,13, or using
non-validated outcome measures14e16. The studies that
demonstrated null effect17e19,21 may have inadequate power
to detect the difference, have placebo effect in the controlTable III
Adverse events of treatments in per protocol population (N¼ 104)
Adverse events Control (n¼ 54) Treatment (n¼ 50)
Shortwave diathermy 4 (7.4%) 4 (8.0%)
Mild pain 2 3
Mild swelling 1 0
Feeling of vasodilatation 2 0
Deterioration of pain,
needed operation
0 1
Quadriceps exercise 18 (33.3%) 20 (37.0%)
Increased crepitus sound 6 8
Mild tightness of muscle 13 16
Fatigue 3 0
Mild pain 4 2
Some cases may have multiple adverse events.
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power to demonstrate the equivalence, or use non-validated
outcome measures.
In 2006, McCarthy et al. published a systematic review on
pulsed electromagnetic ﬁeld (PEMF) or SWD therapy for
pain relief in knee OA29. The authors found ﬁve good quality
randomized controlled trials (RCTs) reported in 1996e
200520,22,30e32. These ﬁve studies used different types of
PEMF and different protocols of treatment. All of them
showed null effect of the SWD. The authors performed
meta-analysis and concluded that the PEMF has little value
in the management of knee OA. Among these ﬁve studies,
the one by Laufer et al. had the treatment protocol similar to
ours but it had limitations including non-randomized alloca-
tion and small sample size per group31; therefore, the no dif-
ference does not have enough power to show equivalence.
Our present double-blind randomized, placebo-controlled
trial had enough power to show the equivalence of the
Thai WOMAC total score, considering that a MCII of WO-
MAC total score for knee OA is 1 cm27. In 2005, Tubach
et al. reported that the MCII varied with the baseline WO-
MAC score. According to their study, the patients with inter-
mediate baseline score (similar to our participants’ score)
need MCII of 27.4 (95% CI 29.7 to 24.6) and 11.8
(95% CI 13.0 to 10.4) mm for WOMAC pain and function
scores, respectively33. With this large MCII, the sample size
needed to demonstrate either the superiority or the equiva-
lence is smaller than the one used in our study. Therefore,
our study had enough power to declare the equivalence.
Moreover, all of the studies in the review by McCarthy
et al.29 might also show equivalent outcomes.
The equivalent outcome cannot completely reject the
possible beneﬁcial effect of SWD as was shown in in vitro
and in animal studies, or in clinical trials using surrogate
outcomes11,32,34,35. It is possible that an RCT using an inac-
tive control may be able to demonstrate this effect. How-
ever, we cannot use the inactive control in our study
because effective standard treatments have been available
by the time we began the study. The recommended treat-
ments for all OA patients include lifestyle modiﬁcation
(i.e., weight reduction and exercise) and analgesic medica-
tions (paracetamol and/or NSAIDs)6,7, both of which were
prescribed to all participants in our study. These basic treat-
ments caused improvement with time in symptoms and
functions in our participants. The addition of SWD did not
add any beneﬁt over the basic treatments.
The strength of the present study is a well-conducted pro-
cess. We were meticulous about the blinding technique
which was very important for the study using subjective out-
comes. However, the technique could not efﬁciently blind
the participants in the treatment group. Although none of
the participants had previously undergone SWD therapy,
80% of the treatment group correctly told that they got the
treatment whereas 52% of the control group wrongly told
that they got the treatment (data not shown). In spite of
such bias, the treatment group did not have better out-
comes than the control group did.
The present study has limitations in generalizability.
Although our study population was peri-/post-menopausal
women who formed the majority of the knee OA patients,
all of them were Thai whose lifestyle might be different
from that of other ethnic groups. The relatively short dura-
tion of treatment might not be sufﬁcient to show the beneﬁt
of SWD treatment. Only one SWD machine with a unique
output power was used in order to homogenize the provided
treatment. All of these conditions would make the results in-
applicable to different situations such as populations withdifferent baseline characteristics, different treatment proto-
col, or the treatment using a different type of SWD with
a different output power. However, the review by McCarthy
et al. demonstrated that different studies using various
types and regimens of SWD had the similar outcomes,
i.e., null effect29. It is possible that further study of SWD
would not give a different result.
In conclusion, according to our criteria of equivalence
(1 cm for Thai WOMAC total score), the addition of SWD
to the exercise program for knee OA in peri-/post-meno-
pausal women is not superior to the exercise program alone.
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